TITRE |
Chimioradiothérapie externe radicale chez les patients atteints d’un cancer rectal : une approche attentiste |
PROTOCOLE ID |
14-407 GEN |
CLINICAL TRIAL.gov ID |
NCT03001362 |
TYPE(S) DE CANCER |
Colorectal |
PHASE |
Phase II |
TYPE D'ÉTUDE |
|
INSTITUTION |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
1001 boul. Décarie
|
VILLE |
Montréal
|
INVESTIGATEUR(RICE) PRINCIPAL(E) |
Neil Kopek
|
COORDONATEUR(RICE) |
Tatiana Carvalho tatiana.carvalho@muhc.mcgill.ca 514-934-1934 poste 43698
|
STATUT |
Actif en recrutement
|
CRITÈRES D'ÉLIGIBILITÉ |
(EN)
|
CRITÈRES D'EXCLUSION |
(EN)
- Previous radiotherapy to the pelvis (including brachytherapy)
- Enlarged extramesorectal nodes
- Uncontrolled cardiorespiratory comorbidity (includes patients with inadequately controlled angina or myocardial infarction within 6 months of randomisation)
- T1N0 disease without extra-mural venous invasion
- Unequivocal evidence of metastatic disease (includes resectable metastases)
- Major impairment of bowel function without defunctioning stoma/ileostomy (baseline grade 3 diarrhoea or clinically significant faecal incontinence)
- History of another malignancy within the last 5 years except successfully treated basal cell cancer of skin or carcinoma in situ of uterine cervix.
- Known dihydropyrimidine dehydrogenase deficiency
- Known Gilberts disease (hyperbilirubinaemia)
- Taking warfarin or phenytoin or sorivudine
- Gastrointestinal disorder which would interfere with oral therapy and its bioavailability
- Pregnant, lactating, or pre-menopausal women not using adequate contraception
- Unfit to receive any study treatment or subsequent surgical resection
|